jRCT2021210050
Untitled Trial
A phase ll multi center, single arm, safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy
Novartis Pharma. K.K.·Japan Registry Clinical TrialRecruitment Completed
Study focus
- Disease/Condition
- AML
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Novartis Pharma. K.K.
- Location
- France;Italy;Taiwan;Australia;United States of America;Canada;Korea;Germany;Spain
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2021210050
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2021210050 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharma. K.K. and is currently Recruitment Completed. The study focuses on AML.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.